Aridis Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Aridis Pharmaceuticals generated cash of -$29,127,000, which is less than the previous year. Cash used in financing activities reached the amount of $14,782,000 last year. Net change in cash is therefore -$14,427,000.
Cash Flow
| 2016 | -6.09M | -15K | 25.50M |
|---|---|---|---|
| 2017 | -17.55M | -698K | 21.06M |
| 2018 | -24.27M | -1.67M | 25.08M |
| 2019 | -8.15M | -174K | 4.99M |
| 2020 | -20.47M | -367K | 8.67M |
| 2021 | -22.93M | -530K | 34.72M |
| 2022 | -29.12M | -82K | 14.78M |
ARDS Cash Flow Statement (2016 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 19.98M | 8.73M | 20.89M | 24.23M | 25.09M | 22.29M | 2.89M |
Operating activities | |||||||
Net income | -30.37M | -42.19M | -22.33M | -29.68M | -22.10M | -24.65M | -8.42M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 487K | 435K | 337K | 338K | 283K | 62K | 23K |
Stock-based compensation expense | 1.47M | 2.25M | 2.12M | 2.01M | 0 | 1.60M | 858K |
| Deferred income tax benefit | 1.47M | 2.25M | 2.12M | 2.01M | 0 | 1.60M | 858K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | -1M | 0 | 0 | 1.66M | -1.66M | 67K | 454K |
Inventories | 0 | 0 | 0 | -2.54M | -2.85M | -341K | -44K |
Accounts payable | -2.93M | 2.65M | -83K | -469K | 2.09M | 431K | 319K |
Cash generated by operating activities | -29.12M | -22.93M | -20.47M | -8.15M | -24.27M | -17.55M | -6.09M |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | -1M | 0 | 0 |
Investments In Property Plant And Equipment | -82K | -530K | -367K | -174K | -677K | -698K | -15K |
Acquisitions Net | 0 | 0 | 0 | 0 | -1M | 0 | 0 |
Cash generated by investing activities | -82K | -530K | -367K | -174K | -1.67M | -698K | -15K |
Financing activities | |||||||
Common Stock Issued | 12.60M | 29.71M | 7.94M | 4.95M | 25.07M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 3.2M | -5M | -715K | 0 | 0 | 0 | -300K |
Cash used in financing activities | 14.78M | 34.72M | 8.67M | 4.99M | 25.08M | 21.06M | 25.50M |
Net Change In Cash | -14.42M | 11.25M | -12.16M | -3.34M | -859K | 2.80M | 19.39M |
Cash at end of period | 5.55M | 19.98M | 8.73M | 20.89M | 24.23M | 25.09M | 22.29M |
| Data source | Data source | Data source | Data source | Data source |